Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 180

Similar articles for PubMed (Select 16943718)

1.

Biomarkers of outcome from cardiovascular disease.

Khuseyinova N, Koenig W.

Curr Opin Crit Care. 2006 Oct;12(5):412-9. Review.

PMID:
16943718
2.

Inflammatory markers and coronary heart disease.

Rifai N, Ridker PM.

Curr Opin Lipidol. 2002 Aug;13(4):383-9. Review.

PMID:
12151853
3.
4.

Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein.

Koenig W.

Int J Cardiol. 2005 Feb 15;98(2):199-206. Review.

PMID:
15686768
5.

High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease.

Rosenson RS, Koenig W.

Curr Opin Cardiol. 2002 Jul;17(4):325-31. Review.

PMID:
12151864
7.

Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.

Corson MA, Jones PH, Davidson MH.

Am J Cardiol. 2008 Jun 16;101(12A):41F-50F. doi: 10.1016/j.amjcard.2008.04.018. Review.

PMID:
18549871
8.

Indices of low-grade inflammation in polycystic ovary syndrome.

Diamanti-Kandarakis E, Paterakis T, Kandarakis HA.

Ann N Y Acad Sci. 2006 Dec;1092:175-86. Review.

PMID:
17308143
9.

Inflammation markers and coronary heart disease.

Tracy RP.

Curr Opin Lipidol. 1999 Oct;10(5):435-41. Review.

PMID:
10554706
10.

Systemic low-grade inflammation and risk of coronary heart disease: results from the MONICA/KORA Augsburg cohort studies.

Koenig W, Meisinger C, Baumert J, Khuseyinova N, Löwel H.

Gesundheitswesen. 2005 Aug;67 Suppl 1:S62-7.

PMID:
16032519
11.

[High sensivity C-reactive protein as a complement to classical methods in the evaluation of coronary event's risk].

Markuszewski L, Pietruszyński R, Wojdyn M, Retelewska W.

Pol Merkur Lekarski. 2006 Apr;20(118):448-52. Review. Polish.

PMID:
16886574
12.

Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study.

Zakai NA, Katz R, Jenny NS, Psaty BM, Reiner AP, Schwartz SM, Cushman M.

J Thromb Haemost. 2007 Jun;5(6):1128-35.

PMID:
17388967
13.

Leukocyte count and coronary heart disease: implications for risk assessment.

Madjid M, Awan I, Willerson JT, Casscells SW.

J Am Coll Cardiol. 2004 Nov 16;44(10):1945-56. Review.

14.

Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy.

Kaplan RC, Frishman WH.

Heart Dis. 2001 Sep-Oct;3(5):326-32. Review.

PMID:
11975814
15.

C-reactive protein as a risk factor versus risk marker.

de Maat MP, Trion A.

Curr Opin Lipidol. 2004 Dec;15(6):651-7. Review.

PMID:
15529024
17.

Health screening packages: the place of measuring C-reactive protein.

Wong MS.

Singapore Med J. 2006 Oct;47(10):827-9. No abstract available.

18.

CRP and the risk of atherosclerotic events.

Calabrò P, Golia E, Yeh ET.

Semin Immunopathol. 2009 Jun;31(1):79-94. doi: 10.1007/s00281-009-0149-4. Epub 2009 May 5. Review.

PMID:
19415283
19.

C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders?

Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P.

J Hypertens. 2003 Oct;21(10):1787-803. Review.

PMID:
14508181
20.

[Inflammation and C-reactive protein in cardiovascular disease].

Munk PS, Larsen AI.

Tidsskr Nor Laegeforen. 2009 Jun 11;129(12):1221-4. doi: 10.4045/tidsskr.08.0011. Review. Norwegian.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk